The Practice Advancement Initiative from the American Society of Health-System Pharmacists seeks to transform how pharmacists care for patients by empowering the pharmacy team to take responsibility for medication-use outcomes."
Integrated, coordinated care and access to the electronic medical record provide many unique opportunities to enhance overall care and decrease costs associated with hepatitis C therapy.
The cost of complex therapies is soaring, and the challenge is to deliver access to these medications in the most cost-effective and clinically appropriate site of service.
Recently published data from a survey of commercial health plans reveal the latest trends and emerging strategies in oncology management.
Advances in biotechnology have improved the production and recombination of antibodies, leading to improvements in monoclonal antibody therapies.
Health care organizations harness technology in their quest to boost medication adherence.
Approximately 29.1 million individuals in the United States have diabetes, and an estimated 8.1 million cases are undiagnosed.
Pharmacists must juggle the delicate balance of integrating clinical services into traditional dispensing environments, while being forced into performance metrics set forth by corporate entities.
Technicians pick up administrative tasks so pharmacists can spend more time on direct patient care.
The CDC has reported that 20% to 50% of all antibiotics prescribed in US acute care hospitals are either unnecessary or inappropriate, resulting in avoidable adverse effects, bacterial resistance, and an increased incidence of infection.
Evolocumab, when used with diet, can be used as monotherapy or in combination with other lipid-lowering agents for the prevention of cardiovascular events.
Opioid therapies are often prescribed for sleep disturbance due to their effect on multiple neurochemical pathways associated with sleep.
This study presents the first information available regarding enablement and use by state and area characteristics of electronic prescribing of controlled substances by prescribers and pharmacy systems in from an e-prescribing network.
In a short time, COVID-19 has increased our dependency on technology and pharmaceutical companies are actively investigating this digital transformation.
Health care providers participating in the 340B program are prohibited from contributing to duplicate discounts, or the scenario that exists when a manufacturer provides a discounted 340B price and a rebate to Medicaid for the same drug.
Antimicrobial stewardship programs have been around for some time. However, a tipping point has yet to be achieved where most hospitals and long-term care facilities have effective programs.
This study examined the impact of a pregabalin step therapy policy on utilization and medical costs in Humana’s Medicare and commercial plans.
Position your specialty pharmacy to access limited distribution drugs.
Current treatment guidelines utilized by healthcare provider organizations and managed care organization insurance coverage policies for growth hormone therapy are reviewed.
Gaining approval from insurance companies for highly effective new hepatitis C virus treatments is fraught with challenges for patients.
Patients with a new diagnosis of acute coronary syndrome often do not know a great deal about their disease, its treatment, or the lifestyle changes needed to prevent recurrence.
This article is an early utilization review of newer, more effective, and more costly regimens for the treatment of hepatitis C.
The action by NICE highlights discussion on both sides of the Atlantic about the cost of PCSK9 inhibitors, which lower LDL cholesterol.